Proteomics Market Updates

Global Proteomics Market size was valued at USD 31.8 billion in 2023 and is poised to grow from USD 36.16 billion in 2024 to USD 100.99 billion by 2032, growing at a CAGR of 13.7% during the forecast period (2025-2032).

To stay competitive in the proteomics market, companies are focusing on strategic acquisitions and partnerships. For example, Danaher’s acquisition of Abcam expanded its capabilities in proteomics tools and reagents. Partnerships like Bruker Corporation’s collaboration with Biognosys AG are driving innovation through integrated technologies. These strategies help companies enhance their product offerings, accelerate technological advancements, and strengthen market presence. By consolidating resources and expanding expertise, these players ensure sustained growth and remain at the forefront of proteomics innovation.'Thermo Fisher Scientific', 'Creative Diagnostics', 'Agilent Technologies', 'Bruker Corporation', 'Danaher Corporation', 'Waters Corporation', 'Bio-Rad Laboratories', 'PerkinElmer', 'Creative Proteomics', 'Promega Corporation', 'LI-COR Biosciences', 'Horiba Ltd', 'Illumina, Inc.', 'SomaLogic', 'NanoString Technologies', 'Proteome Sciences', 'Shimadzu Corporation', 'Merck KGaA', 'Enzo Life Sciences', 'Akoya Biosciences'

In 2023, Waters Corporation launched an advanced high-resolution mass spectrometry system that enhances the accuracy and speed of proteomics research, enabling the discovery of new biomarkers and disease targets. This innovation has contributed to a notable increase in sales for their analytical instruments division. The introduction of such cutting-edge technology is revolutionizing how researchers study proteins, leading to faster drug discovery and more accurate disease diagnosis, as well as paving the way for personalized medicine.

Short-Term: In the short term, the proteomics market is experiencing a sharp increase in demand driven by targeted drug discovery efforts, especially in oncology and infectious diseases. Pharmaceutical and biotech companies are leveraging proteomic technologies to identify biomarkers and therapeutic targets faster. Additionally, COVID-19 accelerated proteomics adoption in vaccine development and diagnostics, further boosting the market. Government funding and collaboration between research institutes are supporting rapid adoption of mass spectrometry and protein microarrays.

North America remains the dominant geography in the proteomics industry worldwide, fueled by robust biomedical infrastructure, significant public-private investments in life sciences, and increasing demand for personalized medicine. Robust academic and clinical research environments are a major driver for driving technological innovation, particularly in proteomic data analysis and biomarker discovery. Interdisciplinary interactions between academia, healthcare, and industry continue to fuel the advancement of clinical proteomics applications, primarily in cancer, neurology, and the management of chronic diseases.